AKBA logo

AKBA
Akebia Therapeutics Inc.

20,751
Mkt Cap
$273.62M
Volume
813,612.00
52W High
$4.08
52W Low
$0.875
PE Ratio
-13.21
AKBA Fundamentals
Price
$1.02
Prev Close
$1.02
Open
$1.03
50D MA
$1.35
Beta
1.27
Avg. Volume
2.25M
EPS (Annual)
-$0.0208
P/B
9.98
Rev/Employee
$1.22M
$443.78
Loading...
Loading...
News
all
press releases
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
More News
News Placeholder
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday
Akebia Therapeutics (NASDAQ:AKBA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-akebia-therapeutics-inc-stock...
News Placeholder
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
News Placeholder
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +64.71% and +29.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
News Placeholder
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
News Placeholder
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below 200-Day Moving Average - Should You Sell...
News Placeholder
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat.com...
News Placeholder
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Akebia Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available